Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from infections, diabetes complications and an accident contributed to an ...

The biggest stories of the day delivered to your inbox.

March 31 (Reuters) - Apple (AAPL.O), opens new tab is testing a feature that would let Siri process multiple requests in ‌a single query, bringing the virtual assistant more in line with the ...

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma ” or the “Company ”), a biopharmaceutical company dedicated to building a ...

Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study The first poster, “Intracranial Efficacy of ...

Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” ...

Mezigdomide plus carfilzomib and dexamethasone improves progression free survival in patients with relapsed or refractory multiple myeloma. Positive interim results were announced from a phase 3 trial ...

Interim analysis demonstrated superior progression-free survival with MeziKd versus carfilzomib/dexamethasone in anti-CD38– and lenalidomide-exposed relapsed ...

A second phase 3 study of Roche’s fenebrutinib in relapsing multiple sclerosis (RMS) has hit its primary endpoint, positioning the company to submit the BTK inhibitor for approval. But the discovery ...

You can't have missed the stablecoin vibe. While bitcoin BTC $79,609.57 and the rest of the crypto market are in the doldrums after falling from record highs in October, everyone else is talking about ...